“Therapeutic and adverse effects of standard-dose and low-dose meglumine antimoniate during systemic treatment of Syrian cutaneous leishmaniasis patients”, J Pak Assoc Dermatol, vol. 24, no. 2, pp. 115–121, Dec. 2016, doi: 10.66344/jpad.v24i2.189.